It can be challenging to find information about Alzheimer’s clinical trials, let alone find trial participants’ first-hand accounts of their experiences. People living with…
A new anti-amyloid drug for Alzheimer’s disease might receive FDA approval as soon as this month. Although anti-amyloid drugs have shown us that clear…
Today, the Food and Drug Administration’s (FDA) eleven-person advisory committee unanimously voted, (11-0) that Eli Lilly’s anti-amyloid Alzheimer’s drug donanemab was effective, and that…
Mild cognitive impairment – an early stage of dementia – is widely under-diagnosed in people 65 and older. That is the key takeaway of…
Diagnosed with Alzheimer’s and one of the relative few who has gotten a prescription for the new, disease-modifying anti-amyloid drug Leqembi? If you live…
There are different modalities of drugs, delivered in different formats, that work in different ways. One type of drug you may encounter often is…
In the last three years, amyloid plaque-busting drugs Aduhelm (now discontinued) and Leqembi have been approved by the FDA for treating patients in the…
A recent study reported that sildenafil, sold under the brand name Viagra, and other medicines from the same group called phosphodiesterase type-5 inhibitors may…
The monoclonal antibody drugs targeting the brain’s amyloid plaques dominated the news cycle in 2023. Eisai and Biogen’s Leqembi was approved by the FDA…
Alzheimer’s disease affects millions of people worldwide, and as the world’s population ages, that number is going up. But, the exact cause of Alzheimer’s…
Neurologists and Alzheimer’s research experts explain the side effect known as ARIA — or brain bleeds — associated with the use of anti-amyloid monoclonal antibody…
Biogen and Eisai’s monoclonal antibody drugs for Alzheimer’s — Aduhelm (now off the market) and Leqembi (fully approved by the FDA in 2023) —…
Biogen renounced ownership of their controversial anti-Alzheimer’s drug Aduhelm after years of dismal sales. The company is also halting an ongoing clinical trial set…
The process of finding new treatments for Alzheimer’s disease is one of trial and error — and every “failed” trial generates invaluable new data…
Dementia can be isolating — for the person living with the disease, and for caregivers. It can also be generative. For a number of…